ClinicalTrials.gg
RecruitingNCT07716449Updated Oct 19, 2026

QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

A Phase 3 interventional study of QLS31905 and Sintilimab in Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Now RecruitingFirst site in China+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS \< 5 , Her-2 Negtive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

02

Conditions studied

  • Gastric or Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in the study and sign the form;
  • (ECOG) performance status score of 0-1;
  • Expected survival time ≥ 12 weeks;
  • or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma;
  • No prior systemic anti-tumor treatment for unresectable locally advanced or disease;
  • Has measurable or non-measurable (but assessable) disease;
  • Patients with adequate cardiac, liver, renal function, etc.

Exclusion criteria

Exclusion Criteria:

  • Known history of allergy to any component of the study drug;
  • Other second primary malignant neoplasm within 5 years;
  • Significant cardiovascular and cerebrovascular disorders within 6 months before randomization;
  • Haemorrhage requiring haemostatic treatment within 3 months prior to randomisation;
  • Previous or current interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, etc;
  • Previous treatment targeting CLDN18.2;
  • Patients with added risks associated with the study or may interfere with the interpretation of study results as determined by the investigator, or deemed unsuitable by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    QLS31905+Oxaliplatin+Capecitabine

    Drug: QLS31905 · Drug: Oxaliplatin · Drug: Capecitabine

  • Active comparator
    Sintilimab+Oxaliplatin+Capecitabine

    Drug: Sintilimab · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • QLS31905 will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.

  • Sintilimab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.

  • Oxaliplatin will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.

  • Capecitabine will be administered orally twice daily (bid).

06

What researchers measure

Primary outcomes

  1. OS

    Overall Survival

    Time frame: Up to 44 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartEst.
Sep 24, 2026was Aug 2026
Primary completionEst.
Sep 2028
CompletionEst.
Aug 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
1 site added — first site in China
Show site
  • Beijing Cancer Hospital · Beijing, China
Oct 19, 2026
Start date
Aug 2026→Sep 24, 2026
Oct 19, 2026
Eligibility
1 inclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedAt least one measurable lesion per RECIST v1.1;
  • AddedHas measurable or non-measurable (but assessable) disease;
Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Progression free survival (PFS)Now OSTime frame: Up to 44 months
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Beijing Cancer Hospital · Beijing, China
    Start date Aug 2026→Sep 24, 2026
    Eligibility 1 inclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAt least one measurable lesion per RECIST v1.1;
    • AddedHas measurable or non-measurable (but assessable) disease;
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Progression free survival (PFS)Now OSTime frame: Up to 44 months
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07716449
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Sep 24, 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Lin Shen, PhD
Contact
doctorshenlin@sina.cn
010-88196358

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905

Start the discussion